Literature DB >> 25924930

Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.

Anastasia Tsiaousidou1,2, A K Tsaroucha3, M Lambropoulou4, M Pitiakoudis3, A Polychronidis5, E Chatzitheoklitos6, K Romanidis3, C Simopoulos3.   

Abstract

Pancreatic cancer (PC) is a leading cause of cancer death worldwide, especially in Western societies. Its aggressive nature and poor prognosis increase the need for identifying new and more accurate diagnostic and prognostic tools. We studied 41 patients who had undergone radical surgical resection for PC, investigated B7H4 protein expression in the PC tissue specimens of these patients by immunohistochemistry and analyzed several clinical and pathological features. The positive expression of the B7H4 antigen was associated with a negative impact of chemotherapy with gemcitabine on patient survival and also correlated with high CA19.9 serum levels and poorly differentiated tumors. Moreover, patients that overexpressed B7H4 antigen had worse prognosis compared to the ones that did not overexpress B7H4. B7H4 antigen is a negative prognostic marker for PC patients and also seems to express resistance of PC patients to chemotherapy with gemcitabine.

Entities:  

Keywords:  B7H4; Biomarkers; Chemotherapy resistance; Immunohistochemistry; Pancreatic cancer

Mesh:

Substances:

Year:  2015        PMID: 25924930     DOI: 10.1007/s10238-015-0352-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  20 in total

Review 1.  Molecular prognostic markers in pancreatic cancer: a systematic review.

Authors:  G Garcea; C P Neal; C J Pattenden; W P Steward; D P Berry
Journal:  Eur J Cancer       Date:  2005-09-16       Impact factor: 9.162

Review 2.  Expression of costimulatory molecule B7-H4 in human malignant tumors.

Authors:  Xiao Zheng; Xiao-Dong Li; Chang-Ping Wu; Bin-Feng Lu; Jing-Ting Jiang
Journal:  Onkologie       Date:  2012-10-22

3.  B7-h4 is highly expressed in ductal and lobular breast cancer.

Authors:  Barbara Tringler; Shaoqiu Zhuo; Glenn Pilkington; Kathleen C Torkko; Meenakshi Singh; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 4.  Challenges in developing targeted therapy for pancreatic adenocarcinoma.

Authors:  Devalingam Mahalingam; Francis Giles
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

5.  Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway.

Authors:  Gee-Chen Chang; Shih-Lan Hsu; Jia-Rong Tsai; Wen-Jun Wu; Chih-Yi Chen; Gwo-Tarng Sheu
Journal:  Eur J Pharmacol       Date:  2004-10-19       Impact factor: 4.432

Review 6.  A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.

Authors:  Janelle M Fauci; J Michael Straughn; Soldano Ferrone; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2012-08-19       Impact factor: 5.482

7.  Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Authors:  Nida S Awadallah; Kenneth R Shroyer; Daniel A Langer; Kathleen C Torkko; Yang K Chen; Joel S Bentz; Jackie Papkoff; Wenhui Liu; S Russell Nash; Raj J Shah
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

8.  B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.

Authors:  Takashi Miyatake; Barbara Tringler; Wenhui Liu; Shu-Hui Liu; Jackie Papkoff; Takayuki Enomoto; Kathleen C Torkko; Donna L Dehn; Ashanta Swisher; Kenneth R Shroyer
Journal:  Gynecol Oncol       Date:  2007-05-16       Impact factor: 5.482

9.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more
  4 in total

1.  The combined expressions of B7H4 and ACOT4 in cancer-associated fibroblasts are related to poor prognosis in patients with gastric carcinoma.

Authors:  Qing Li; Yu'e Yang; Xin Jiang; Yufen Jin; Jingyi Wu; Yan Qin; Xiaowei Qi; Yang Cheng; Yong Mao; Dong Hua
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

2.  Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.

Authors:  Na Niu; Weiwei Shen; Yanping Zhong; Robert C Bast; Amir Jazaeri; Anil K Sood; Jinsong Liu
Journal:  Hum Pathol       Date:  2021-04-19       Impact factor: 3.466

Review 3.  The prognostic value of B7-H4 in pancreatic cancer: Systematic review and meta-analysis.

Authors:  Xin Chen; Lianyuan Tao; Chunhui Yuan; Dianrong Xiu
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

4.  B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis.

Authors:  Zibo Meng; Feiyang Wang; Yushun Zhang; Shoukang Li; Heshui Wu
Journal:  Oncotarget       Date:  2017-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.